CO2022001342A2 - Agentes antipalúdicos - Google Patents
Agentes antipalúdicosInfo
- Publication number
- CO2022001342A2 CO2022001342A2 CONC2022/0001342A CO2022001342A CO2022001342A2 CO 2022001342 A2 CO2022001342 A2 CO 2022001342A2 CO 2022001342 A CO2022001342 A CO 2022001342A CO 2022001342 A2 CO2022001342 A2 CO 2022001342A2
- Authority
- CO
- Colombia
- Prior art keywords
- plasmepsin
- treatment
- compounds
- administration
- formula
- Prior art date
Links
- 239000003430 antimalarial agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000004792 malaria Diseases 0.000 abstract 3
- 101710141115 Plasmepsin IX Proteins 0.000 abstract 2
- 101710170193 Plasmepsin X Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000078 anti-malarial effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona métodos para el tratamiento contra la malaria que comprende la administración de compuestos de la Fórmula (I’): (I’) o una sal de este farmacéuticamente aceptable, a un sujeto que lo necesite, en donde las variables son como se definen en la presente. La invención también proporciona usos de los compuestos de la Fórmula (I), como se define en la presente, para inhibir la actividad de plasmepsina X, plasmepsina IX o plasmepsina X y IX, para el tratamiento contra la infección de Plasmodium, y para el tratamiento contra la malaria. También se proporcionan métodos de tratamiento que comprenden además la administración de uno o más compuestos antipalúdicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/100781 WO2021026884A1 (en) | 2019-08-15 | 2019-08-15 | Antimalarial agents |
| PCT/CN2020/103178 WO2021027502A1 (en) | 2019-08-15 | 2020-07-21 | Antimalarial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022001342A2 true CO2022001342A2 (es) | 2022-05-20 |
Family
ID=74570489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0001342A CO2022001342A2 (es) | 2019-08-15 | 2022-02-10 | Agentes antipalúdicos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12350270B2 (es) |
| EP (1) | EP4013742A4 (es) |
| JP (1) | JP7116859B2 (es) |
| KR (1) | KR102752456B1 (es) |
| CN (1) | CN114555564B (es) |
| AR (1) | AR119784A1 (es) |
| AU (1) | AU2020328678B2 (es) |
| BR (1) | BR112022002692A2 (es) |
| CA (1) | CA3147665C (es) |
| CL (1) | CL2022000329A1 (es) |
| CO (1) | CO2022001342A2 (es) |
| CR (1) | CR20220067A (es) |
| DO (1) | DOP2022000037A (es) |
| EC (1) | ECSP22011746A (es) |
| GE (2) | GEP20257744B (es) |
| IL (1) | IL290525B2 (es) |
| JO (1) | JOP20220038A1 (es) |
| MX (1) | MX2022001768A (es) |
| PH (1) | PH12022550350A1 (es) |
| TW (1) | TWI881998B (es) |
| UA (1) | UA128074C2 (es) |
| WO (2) | WO2021026884A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023102747A1 (en) * | 2021-12-07 | 2023-06-15 | Merck Sharp & Dohme Llc | Antimalarial agents |
| US20230355622A1 (en) * | 2020-09-23 | 2023-11-09 | Merck Sharp & Dohme Llc | Methods of chemovaccination against plasmodium infections |
| EP4288055A4 (en) * | 2021-02-05 | 2024-12-18 | Merck Sharp & Dohme LLC | <smallcaps/>? ? ?lasmodium? ? ? ? ?chemovaccination against pinfection with selective plasmepsin x inhibitors |
| WO2024254795A1 (en) * | 2023-06-14 | 2024-12-19 | Merck Sharp & Dohme Llc | Antimalaria agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058311A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CN101351460A (zh) | 2005-10-31 | 2009-01-21 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2017089453A1 (en) * | 2015-11-25 | 2017-06-01 | Ucb Biopharma Sprl | Iminotetrahydropyrimidinone derivatives as plasmepsin v inhibitors |
| EP3416647A4 (en) * | 2016-02-18 | 2019-10-23 | Merck Sharp & Dohme Corp. | N3-SUBSTITUTED IMINOPYRIMIDINONE AS ANTIMALARIAMIDAL |
| US20190046507A1 (en) | 2016-02-18 | 2019-02-14 | Merck Sharp & Dohme Corp. | Compounds for the treatment of malaria |
| GB201603104D0 (en) * | 2016-02-23 | 2016-04-06 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201906804D0 (en) * | 2019-05-14 | 2019-06-26 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2021155612A1 (en) * | 2020-02-09 | 2021-08-12 | Merck Sharp & Dohme Corp. | Antimalarial agents |
-
2019
- 2019-08-15 WO PCT/CN2019/100781 patent/WO2021026884A1/en not_active Ceased
-
2020
- 2020-07-21 MX MX2022001768A patent/MX2022001768A/es unknown
- 2020-07-21 KR KR1020227007941A patent/KR102752456B1/ko active Active
- 2020-07-21 CN CN202080072179.5A patent/CN114555564B/zh active Active
- 2020-07-21 EP EP20852190.6A patent/EP4013742A4/en active Pending
- 2020-07-21 GE GEAP202015903A patent/GEP20257744B/en unknown
- 2020-07-21 JO JOP/2022/0038A patent/JOP20220038A1/ar unknown
- 2020-07-21 CA CA3147665A patent/CA3147665C/en active Active
- 2020-07-21 GE GEAP202415903A patent/GEAP202415903A/en unknown
- 2020-07-21 BR BR112022002692A patent/BR112022002692A2/pt unknown
- 2020-07-21 PH PH1/2022/550350A patent/PH12022550350A1/en unknown
- 2020-07-21 UA UAA202200963A patent/UA128074C2/uk unknown
- 2020-07-21 AU AU2020328678A patent/AU2020328678B2/en active Active
- 2020-07-21 IL IL290525A patent/IL290525B2/en unknown
- 2020-07-21 US US17/633,655 patent/US12350270B2/en active Active
- 2020-07-21 CR CR20220067A patent/CR20220067A/es unknown
- 2020-07-21 JP JP2022508854A patent/JP7116859B2/ja active Active
- 2020-07-21 WO PCT/CN2020/103178 patent/WO2021027502A1/en not_active Ceased
- 2020-08-14 TW TW109127798A patent/TWI881998B/zh active
- 2020-08-14 AR ARP200102325A patent/AR119784A1/es unknown
-
2022
- 2022-02-08 CL CL2022000329A patent/CL2022000329A1/es unknown
- 2022-02-10 CO CONC2022/0001342A patent/CO2022001342A2/es unknown
- 2022-02-11 DO DO2022000037A patent/DOP2022000037A/es unknown
- 2022-02-14 EC ECSENADI202211746A patent/ECSP22011746A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001342A2 (es) | Agentes antipalúdicos | |
| MX2021005898A (es) | Terapia de combinacion que incluye un inhibidor de krasg12c y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
| NI202000101A (es) | Compuestos antagonistas de pcsk9 | |
| MX2021001558A (es) | Inhibidores de itk de pirrolopirimidina. | |
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| WO2017142825A3 (en) | N3-substituted iminopyrimidinones as antimalarial agents | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| UY39559A (es) | Compuestos y su uso | |
| NI201200059A (es) | PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| DOP2015000169A (es) | Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2022002649A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento. | |
| MX2020005006A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| RU2017134285A (ru) | Борсодержащие низкомолекулярные соединения как антипротозойные агенты | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| CL2024001683A1 (es) | Agentes contra el paludismo. | |
| AR124136A1 (es) | Nuevos compuestos orgánicos | |
| AR132760A1 (es) | Compuestos heterocíclicos y usos de estos |